WO2014132060A1 - Compositions pour le soin de la peau - Google Patents

Compositions pour le soin de la peau Download PDF

Info

Publication number
WO2014132060A1
WO2014132060A1 PCT/GB2014/050580 GB2014050580W WO2014132060A1 WO 2014132060 A1 WO2014132060 A1 WO 2014132060A1 GB 2014050580 W GB2014050580 W GB 2014050580W WO 2014132060 A1 WO2014132060 A1 WO 2014132060A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skincare
percent
combination
salt
Prior art date
Application number
PCT/GB2014/050580
Other languages
English (en)
Inventor
Clotilde CHEIGNON
Diane Marie Pavis
Original Assignee
Reckitt Benckiser (Brands) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser (Brands) Limited filed Critical Reckitt Benckiser (Brands) Limited
Publication of WO2014132060A1 publication Critical patent/WO2014132060A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application

Definitions

  • This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions.
  • Acne vulgaris is a chronic inflammatory condition of the pilosebaceous units of the skin, which is particularly prevalent in adolescents.
  • the condition generally causes the formation, on the skin, of comedones, red papules, pustules and sometimes cysts. This is unsightly and furthermore, if untreated, acne can lead to scarring of the skin.
  • the major causes of acne are thought to be an increase in sebum production, an increased presence of propionibacterium acne (P. acne), blockage of the pilosebaceus duct and the production of inflammation.
  • Salicylic acid is known to be effective in the treatment of acne. It is a topical keratolytic agent that works by dissolving the intercellular cement that holds epithelial cells together. Salicylic acid is used in a variety of over-the-counter acne remedies.
  • salicylic acid In order to improve the efficacy of topical acne treatments, it is desired to formulate salicylic acid with one or more control agents to regulate the inflammatory effects sometimes observed, such as local skin peeling and discomfort such as burning and skin reddening.
  • compositions (a) and (b) each suitable for topical application to the skin, wherein composition (a) comprises salicylic acid or a salt thereof, combined with at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide and composition (b) comprises at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide.
  • this treatment provides advantages over existing acne treatments, particularly in tolerance of the acne treatment by the skin reduction in inflammation in the affected skin and/or a soothing effect. Without wishing to be bound by any theory, it is believed that this treatment may have an effect in reducing the severity of the acne and hence any associated marks or scarring that can occur; furthermore, cutaneous irritation may be reduced.
  • Salicylic acid is preferably incorporated into composition (a) according to the invention as the free acid.
  • the pH of the composition may, and generally will, be such that the salicylic acid exists in the composition in dissociated form.
  • the composition may well contain cationic counterions, the salicylic acid may then be thought of as being present in salt form.
  • the salicylic acid may be incorporated into the composition already in salt form, eg as a salt with a Group I metal, such as sodium salicylate.
  • any and all references to salicylic acid should be taken to encompass references to the acid and to dissociated forms and salts thereof.
  • the concentration of salicylic acid in the composition according to the invention is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
  • the concentration of salicylic acid is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
  • the concentration of salicylic acid may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
  • a particularly preferred concentration of salicylic acid is 2 percent by weight.
  • the concentration of niacinamide when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
  • the concentration of niacinamide is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
  • the concentration of niacinamide may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
  • a particularly preferred concentration of niacinamide is 2 percent by weight.
  • the concentration of lactic acid or salt thereof when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
  • the concentration of lactic acid or a salt or a derivative thereof is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
  • the concentration of lactic acid or a salt or a derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
  • a particularly preferred concentration of lactic acid or a salt or a derivative thereof is 2 percent by weight.
  • the concentration of glycyrrhizinic acid or a salt or a derivative thereof when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
  • the concentration of glycyrrhizinic acid or a salt or a derivative thereof is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
  • concentration of glycyrrhizinic acid or a salt or a derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
  • concentration of glycyrrhizinic acid or a salt or a derivative thereof is 2 percent by weight.
  • composition (a) comprises 0.1 to 5 wt% salicylic acid, or a salt thereof, in combination with 0.1 to 5 wt% niacinamide; and composition (b) comprises 0.1 to 5 wt% niacinamide. More preferably composition (a) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide; and composition (b) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide. In a particularly preferred embodiment of the present invention, composition (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with 2.0wt% niacinamide; and composition (b) comprises 2.0wt% niacinamide.
  • composition (a) (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid; and composition (b) comprises 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid.
  • the composition is preferably prepared with a pH in the range 2.5 to 8.0, more preferably 3.0 to 7.0, and particularly a pH in the range 3.5 to 6.0, e.g. about pH 4.5 or pH 5.5.
  • compositions (a) and (b) according to the invention may be formulated in numerous forms. However, the compositions may often take the form of an aqueous or oily solution or surfactant wash or dispersion or emulsion or a gel.
  • An emulsion may be an oil-in- water emulsion or a water-in- oil emulsion or microemulsion.
  • the oil phase of the emulsion may comprise a) hydrocarbon oils such as paraffin or mineral oils; b) waxes such as beeswax or paraffin wax; c) natural oils such as sunflower oil, apricot kernel oil, shea butter or jojoba oil; d) silicone oils such as dimethicone, cyclomethicone or cetyldimethicone; e) fatty acid esters such as isopropyl palmitate, isopropyl myristate, dioctylmaleate, glyceryl oleate and cetostearyl isononanoate; f) fatty alcohols such as cetyl alcohol or stearyl alcohol and mixtures thereof (eg cetearyl alcohol); g) polypropylene glycol or polyethylene glycol ethers, eg PPG-14 butyl ether; or h) mixtures thereof, for example, the blend of waxes available commercially under the trade name Cutina (Henkel).
  • Emulsifiers used may be any emulsifiers known in the art for use in water-in- oil or oil-in-water emulsions or microemulsions.
  • Known cosmetically acceptable emulsifiers may include: a) sesquioleates such as sorbitan sesquioleate, available commercially for example under the trade name Arlacel 83 (ICI), or polyglyceryl-2- sesquioleate; b) ethoxylated esters of derivatives of natural oils such as the polyethoxylated ester of hydrogenated castor oil available commercially for example under the trade name Arlacel 989 (ICI); c) silicone emulsifiers such as silicone polyols available commercially for example under the trade name ABIL WS08 (Th.
  • emulsifiers such as fatty acid soaps e.g. potassium stearate and fatty acid sulphates e.g. sodium cetostearyl sulphate available commercially under the trade name Dehydag (Henkel); e) ethoxylated fatty alcohols, for example the emulsifiers available commercially under the trade name Brij (ICI); f) sorbitan esters, for example the emulsifiers available commercially under the trade name Span (ICI); g) ethoxylated sorbitan esters, for example the emulsifiers available commercially under the trade name Tween (ICI); h) ethoxylated fatty acid esters such as ethoxylated stearates, glyceryl monostearates for example the emulsifiers available commercially under the trade name Myrj (ICI); i) ethoxylated mono-, di-, and
  • Gels provided according to the invention may be aqueous or non-aqueous. Aqueous gels are preferred.
  • the gel will contain a gelling agents in order to give sufficient viscosity to the gel.
  • the gel may further comprise thickening agents.
  • Suitable gelling agents may be hydroxypropyl guar or a copolymer of acryloyl dimethyl tauric acid (or a salt thereof), especially a copolymer of that monomer with another vinylic monomer.
  • the salt may be a salt of a Group I alkali metal, but is more preferably an ammonium salt.
  • suitable copolymer gelling agents are ammonium acryloyl dimethyl taurate / vinyl pyrrolidone copolymer, ammonium acryloyl dimethyl taurate / Beheneth-25 methacrylate copolymer, ammonium acryloyldimethyltaurate / vinyl formamide copolymer These materials are available from Clariant GmbH in the range of products under the trade name Aristoflex.
  • thickening agents may also be used according to the nature of the liquid carrier and the viscosity required.
  • Thickeners that are water-soluble or hydrophilic are preferred, and examples include acrylic acid polymers, eg those available commercially under the trade name Carbopol (B.F. Goodrich), modified celluloses, eg hydroxypropylmethylcellulose or hydroxyethylcellulose available commercially under the trade name Natrosol (Hercules), alkylgalactomanans available under the trade name N-Hance, xanthan gum, cetyl alcohol and sodium chloride.
  • the amount of gelling and/or thickening agent in the composition will each preferably lie in the range 0.1 to 5 percent w/w, more preferably 0.5 to 5 percent w/w. Typically, the amount of gelling and/or thickening agent will each be less than 3 percent w/w, eg about 1 percent w/w or about 2 percent w/w.
  • the composition according to the invention preferably has a viscosity of from about 10,000 mPa.s to about 200,000 mPa.s, Viscosity may be measured using a Brookfield RVT viscometer equipped with a T bar C rotating at 5rpm for 1 minute.
  • the composition should comprise a chelating or sequestering agent, or other agent capable of complexation or other interaction with metal ions present in the composition.
  • chelating or sequestering agents include ethylenediamine tetraacetic acid and its salts, notably the dipotassium and especially the disodium salt.
  • the composition will generally contain a solvent system or other continuous liquid phase. Such a system is preferably aqueous.
  • mixed solvent systems may often be used with advantage.
  • Such a mixed solvent system most preferably comprises water, in admixture with a co-solvent, most preferably a lower (eg Ci-6) alcohol, in particular ethanol and t-butyl alcohol.
  • Preferred aqueous systems comprise water in an amount of at least 25 percent by weight, more preferably at least 35 percent by weight, The upper limit of water will depend on the amounts of other ingredients incorporated in the composition so that the water may form the remainder of the composition up to 100 percent of the composition.
  • composition may additionally comprise other components which will be well known to those skilled in the art.
  • these include, for example: a) Emollients - ingredients that help to maintain the soft, smooth and pliable appearance of skin.
  • Such ingredients may function by their ability to remain on the surface of the skin or in the stratum corneum, and to act as lubricants, reducing or preventing flaking of the skin and improving the skin's appearance.
  • emollients are isopropyl myristate, triglycerides of fatty acids eg lauric triglyceride or capric/caprylic triglyceride, such as the triglyceride available commercially under the trade name Miglyol 810 (Huls UK), and the polypropylene glycol ether of stearyl alcohol known as PPF-15 Stearyl Ether.
  • Particularly preferred emollients are octyldodecanol and polysiloxane compounds, in particular those known as dimethicones.
  • surfactants may be used in compositions according to the invention as solubilisers, or as cleansing agents or foam boosters. Many different classes of surfactant may be suitable for inclusion in the composition according to the invention, and these will be readily apparent to those skilled in the art. Examples of suitable surfactants include anionic surfactants (eg sodium laureth sulphate , non ionic surfactants (eg cocoglucoside) cationic surfactants and/or amphoteric surfactants (eg cocoamidoproyl betaine).
  • anionic surfactants eg sodium laureth sulphate
  • non ionic surfactants eg cocoglucoside
  • amphoteric surfactants eg cocoamidoproyl betaine
  • Polyethylene glycol ethers of alcohols such as isocetyl alcohol (eg Isoceteth- 20), isostearyl alcohol (eg lsosteareth-20), cetyl alcohol (eg Ceteth- 20), oleyl alcohol (eg Oleth-20) and cetearyl alcohol (eg Ceteareth-20).
  • Preservatives - ingredients which prevent or retard microbial growth and thus protect the composition from spoilage. Examples of preservatives include such as propylparaben, bronopol, sodium dehydroacetate, polyhexamethylenebiguanide hydrochloride, isothiazolone and diazolidinylurea.
  • Chelating agents or sequestering agents (sequestrants) - ingredients that have the ability to complex with and inactivate metallic ions in order to prevent their adverse effects on the stability or appearance of the composition, as described above.
  • chelating agents are ethylenediamine tetraacetic acid and its salts, notably the dipotassium and especially the disodium or tetrasodium salt.
  • pH adjusters Ingredients used to control the pH of the composition.
  • pH adjusters are inorganic salts such as sodium hydroxide, and organic bases such as triethanolamine and arginine.
  • Conditioning agents for example distearyldimonium chloride.
  • Perfumes and colourings are examples of pH adjusters.
  • composition according to the invention may be applied and left on the skin to have the desired therapeutic effect or it may be applied and then rinsed off, for example with water for surfactant based formulations.
  • the composition may be applied with the aid of a fibrous material, for example a pad or a wipe.
  • an article comprising a fibrous substrate, for example a material in the form of a pad or a wipe, impregnated with a first skincare composition, composition (a), and a second skincare composition, composition (b), as described in the first aspect of the present invention.
  • a fibrous substrate for example a material in the form of a pad or a wipe
  • the first composition may be applied to one side of the wipe and the second composition may be applied to the second side of the wipe.
  • the first composition may be applied to one end of the wipe and the second composition may be applied to the opposite end of the wipe.
  • Suitable fibrous materials include cellulose or cotton fibres or a mixture thereof.
  • the fibrous material may be impregnated with the composition as a wet wipe which is arranged for immediate use to apply the skincare composition of the present invention to the skin of the user.
  • the fibrous material may be impregnated with the skincare composition and dried to form a dry wipe which requires to be wetted, for example with water, before it can be used.
  • method for the prophylactic or remedial treatment of acne comprises the topical application to the skin of a first skincare composition and a second skincare composition as described in the first aspect of the present invention.
  • the method according to this aspect of the invention may be a therapeutic method, but will often be a primarily cosmetic method, the objective of which is to reduce or eliminate externally visible, and often unsightly, symptoms of acne vulgaris.
  • the method further comprises at least one additional step of topically applying the second composition.
  • the second composition is preferably applied up to three additional times. In one preferred embodiment the second composition is applied one additional time (two times overall). In an alternative preferred embodiment the second composition is applied two additional times (three times overall).
  • a combination of a first skincare composition and a second skincare composition as described in the first aspect of the present invention in the manufacture of a kit for the prophylactic or remedial treatment of acne by topical application of both the first and second compositions to the skin.
  • the term 'derivative' as used herein is intended to cover compounds that are suitable for use in skincare compositions such as esters.
  • formulations of the present application can be prepared using standard methods known to the man skilled in the art.
  • Formulation (a) is applied to the skin and allowed to dry followed by formulation (b).
  • Formulation (b) can be re-applied several times before a repeat of formulation (a) is required.
  • in vitro testing was to evaluate the potential antiinflammatory action of compositions according to the present invention.
  • In vitro tests were carried out as follows: • take an irritant treated EpiDerm (TM) skin model. Initial inflammation was measured by the cytokine release after exposure to a single dose of irritant.
  • TM EpiDerm
  • a salicylic acid/niacinamide combination achieves an anti-inflammatory effect, but that further treatment with a niacinamide-containing formulation according to the invention significantly enhances the inflammatory behaviour of each of these ingredients - by repeating the application of the niacinamide on the top of the salicylic acid during the following hours helps to continue boosting the antiinflammatory effect.
  • This synergistic behaviour is totally unexpected and permits the formulation of products according to the invention such as the one tested which have a broad range of active ingredients to deal with traumas arising from every stage in the lifecycle of a specific acne event or related skin inflammation. Further modifications and developments can be made without departing from the scope of the invention described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison de soins pour la peau comprenant au moins deux compositions (a) et (b) distinctes, chaque composition étant appropriée pour une application topique sur la peau. Selon l'invention, la composition (a) comprend de l'acide salicylique ou un sel de ce dernier, combiné à au moins un composé actif sélectionné dans le groupe constitué par l'acide lactique ou un sel de ce dernier ; de la glycyrrhizine ou un sel ou un dérivé de cette dernière ; et un niacinamide, et la composition (b) comprend au moins un composé actif sélectionné dans le groupe constitué par l'acide lactique ou un sel de ce dernier ; de la glycyrrhizine ou un sel ou un dérivé de cette dernière ; et un niacinamide.
PCT/GB2014/050580 2013-03-01 2014-02-27 Compositions pour le soin de la peau WO2014132060A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1303640.5A GB2511350B (en) 2013-03-01 2013-03-01 Skincare compositions
GB1303640.5 2013-03-01

Publications (1)

Publication Number Publication Date
WO2014132060A1 true WO2014132060A1 (fr) 2014-09-04

Family

ID=48142219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/050580 WO2014132060A1 (fr) 2013-03-01 2014-02-27 Compositions pour le soin de la peau

Country Status (2)

Country Link
GB (1) GB2511350B (fr)
WO (1) WO2014132060A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106214532A (zh) * 2016-07-26 2016-12-14 广州智媛生物科技有限公司 具有控油抑菌功效的组合物及其制备方法
US10874600B2 (en) 2018-06-18 2020-12-29 The Procter & Gamble Company Method for degrading bilirubin in skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US11110049B2 (en) 2017-06-23 2021-09-07 The Procter & Gamble Company Composition and method for improving the appearance of skin
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939940C (fr) 2014-02-21 2023-10-03 Avadim Technologies, Inc. Procede de maintien de catheters uretraux
US10071052B2 (en) 2014-11-19 2018-09-11 Avadim Technologies, Inc. Method for the prevention and treatment of acne

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003779A1 (fr) * 1993-07-30 1995-02-09 Unilever Plc Composition cosmetique renfermant des hydroxyacides
WO1996027365A1 (fr) * 1995-03-03 1996-09-12 Avon Products, Inc. Composition anti-acneique douce
WO2000002593A2 (fr) * 1998-07-09 2000-01-20 Transphyto S.A. Lotion nettoyante et traitante destinee au traitement des comedons
US20030027738A1 (en) * 2001-06-22 2003-02-06 L'oreal Cosmetic and dermatological article
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
DE10338615A1 (de) * 2003-08-22 2005-03-17 Beiersdorf Ag Reinigungsmaske mit pH neutraler Wirkung
WO2011007183A2 (fr) * 2009-07-17 2011-01-20 Reckitt Benckiser Healthcare International Limited Compositions de soins de la peau

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189406B1 (en) * 1999-06-23 2007-03-13 Dennis Gross Composition and method for treating skin
FR2980691B1 (fr) * 2011-09-30 2014-03-14 Galderma Sa Composition de lavage

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003779A1 (fr) * 1993-07-30 1995-02-09 Unilever Plc Composition cosmetique renfermant des hydroxyacides
WO1996027365A1 (fr) * 1995-03-03 1996-09-12 Avon Products, Inc. Composition anti-acneique douce
WO2000002593A2 (fr) * 1998-07-09 2000-01-20 Transphyto S.A. Lotion nettoyante et traitante destinee au traitement des comedons
US20030027738A1 (en) * 2001-06-22 2003-02-06 L'oreal Cosmetic and dermatological article
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
DE10338615A1 (de) * 2003-08-22 2005-03-17 Beiersdorf Ag Reinigungsmaske mit pH neutraler Wirkung
WO2011007183A2 (fr) * 2009-07-17 2011-01-20 Reckitt Benckiser Healthcare International Limited Compositions de soins de la peau

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT DRUG DELIVERY DEC 2010, vol. 7, no. 5, December 2010 (2010-12-01), pages 415 - 420, ISSN: 1875-5704 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 2010 (2010-12-01), PADULA CRISTINA ET AL: "Combined patch containing salicylic acid and nicotinamide: role of drug interaction.", XP002723684, Database accession no. NLM20950260 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106214532A (zh) * 2016-07-26 2016-12-14 广州智媛生物科技有限公司 具有控油抑菌功效的组合物及其制备方法
CN106214532B (zh) * 2016-07-26 2019-04-19 广州智媛生物科技有限公司 具有控油抑菌功效的组合物及其制备方法
US11110049B2 (en) 2017-06-23 2021-09-07 The Procter & Gamble Company Composition and method for improving the appearance of skin
US10874600B2 (en) 2018-06-18 2020-12-29 The Procter & Gamble Company Method for degrading bilirubin in skin
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US11911498B2 (en) 2020-06-01 2024-02-27 The Procter & Gamble Company Low pH skin care composition and methods of using the same
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Also Published As

Publication number Publication date
GB2511350A (en) 2014-09-03
GB201303640D0 (en) 2013-04-17
GB2511350B (en) 2016-11-09

Similar Documents

Publication Publication Date Title
US11135457B2 (en) Skincare compositions
EP1722749B1 (fr) Composition de soin de la peau comprenant de l' acide salicylique
WO2014132060A1 (fr) Compositions pour le soin de la peau
US20070166337A1 (en) Skincare compositions and methods
US20120207812A1 (en) Skincare compositions comprising salicyclic acid
WO2014155111A1 (fr) Compositions de soin de la peau
WO2008053246A1 (fr) Traitement de l'acné
RU2351310C2 (ru) Композиции для ухода за кожей и способы

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14709378

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14709378

Country of ref document: EP

Kind code of ref document: A1